Mechanisms of resistance to immune checkpoint inhibitors.

Br J Cancer 2018 01 2;118(1):9-16. Epub 2018 Jan 2.

Division of Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA.

Immune checkpoint inhibitors (ICI) targeting CTLA-4 and the PD-1/PD-L1 axis have shown unprecedented clinical activity in several types of cancer and are rapidly transforming the practice of medical oncology. Whereas cytotoxic chemotherapy and small molecule inhibitors ('targeted therapies') largely act on cancer cells directly, immune checkpoint inhibitors reinvigorate anti-tumour immune responses by disrupting co-inhibitory T-cell signalling. While resistance routinely develops in patients treated with conventional cancer therapies and targeted therapies, durable responses suggestive of long-lasting immunologic memory are commonly seen in large subsets of patients treated with ICI. However, initial response appears to be a binary event, with most non-responders to single-agent ICI therapy progressing at a rate consistent with the natural history of disease. In addition, late relapses are now emerging with longer follow-up of clinical trial populations, suggesting the emergence of acquired resistance. As robust biomarkers to predict clinical response and/or resistance remain elusive, the mechanisms underlying innate (primary) and acquired (secondary) resistance are largely inferred from pre-clinical studies and correlative clinical data. Improved understanding of molecular and immunologic mechanisms of ICI response (and resistance) may not only identify novel predictive and/or prognostic biomarkers, but also ultimately guide optimal combination/sequencing of ICI therapy in the clinic. Here we review the emerging clinical and pre-clinical data identifying novel mechanisms of innate and acquired resistance to immune checkpoint inhibition.

Download full-text PDF

Source
http://dx.doi.org/10.1038/bjc.2017.434DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765236PMC
January 2018
18 Reads

Publication Analysis

Top Keywords

immune checkpoint
16
checkpoint inhibitors
12
acquired resistance
8
ici therapy
8
patients treated
8
resistance immune
8
resistance
6
clinical
5
ici
5
immune
5
mechanisms ici
4
ici initial
4
treated ici
4
large subsets
4
commonly large
4
ici response
4
initial response
4
subsets patients
4
response appears
4
understanding molecular
4

References

(Supplied by CrossRef)

V Anagnostou et al.
Cancer Discov 2016

SM Ansell et al.
N Engl J Med 2015

Sean P. Arlauckas et al.
Science Translational Medicine 2017

JL Benci et al.
Cell 2016

SD Blackburn et al.
Proc Natl Acad Sci USA 2008

V Bronte et al.
J Exp Med 2005

A Buque et al.
Oncoimmunology 2015

PL Chen et al.
Cancer Discov 2016

KB Chiappinelli et al.
Cell 2015

AI Daud et al.
J Clin Invest 2016

DL Farber et al.
Nat Rev Immunol 2014

Similar Publications